I hate to burst your bubble BUT unfortunately there is no group that will keep MEZI intact due to the Marshall's unwise and untimely filing of the Chapter 11 petition against Medizone. This filing in effect is causing the end of the current company and for a total loss by the shareholders.
The team that was recruited by the Medizone Board led by CEO David Esposito was found by a major technology recruiting company which had expertise in the medical device and biotech fields. This company was...About EMA Partners, LLC
EMA is focused on assisting its clients with mergers, acquisitions, divestitures, intellectual property licensing and sales, recapitalizations, transition planning and other transactional-based services. This the search firm that introduced David Dodd to MZEI. David Dodd had many years as an executive and CEO for many public companies that were super successful. (look up Dodd's business history on LinkedIn.com
“We are very pleased to announce that Medizone International has reached an agreement to have EMA Partners serve as our advisor and investment bank. EMA Partners and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies,” said David Esposito, Chairman and CEO of Medizone International. “As our team has completed several key milestones in the development of AsepticSure, we are preparing to scale our commercial operations in the United States and beyond. We look forward to EMA Partners helping us realize the full potential of our business.”
Dodd and his team had made significant progress in moving forward to commercialize the AseptiSure having the FDA 513(g) filing which is very preliminary to acceptance: Section 513(g) of the Federal Food, Drug, and Cosmetic Act provides a means for device manufacturers to obtain information about the Food and Drug Administration’s views regarding the classification of a device. According to the legislation, a company can submit a written request to the secretary. The secretary will provide a written reply regarding the classification of a device and the associated regulations within sixty days.
Device manufacturers typically submit a 513(g) request to determine whether the regulations pertain to a product and whether a device is subject to the 510(k) regulations. They may submit the request to ascertain whether they need to submit a 510(k) if they intend to modify a device.
Determining the least cumbersome mechanism to get a device approved may also be a reason for a device manufacturer to submit a 513(g). The upcoming FDA meeting is VERY preminary I can not understand how the Marshalls and Dr. Shannor have convinced the TRUSTEE to allow Debtor In Possession (DIP) financing as nothing will result in approvals within the 90 days to be financed for $200K My guess is that the Marshalls are scheming to het a head start in bidding for the companies intellectual property (patents)and screwing all the long suffering shareholders all over again .
From what I have heard from the long suffering investors both stockholders and buyers of company debt in private offerings from Marshall who took salaries and expense reimbursements for himself and his wife despite that the company had very limited revenues and sales, then resigned and created a promissory note from Medizone to himself and his wife still knowing that there still was no revenue at the time or foreseeable future and they could have been plotting to take over the company at a later time with no baggage or liabilities and no stockholder, by filing a Chapter 11 bankruptcy. In my humble opinion this is fraudulent and unethical.
